
GAAP / Non-GAAP Reconciliations

November 5, 2026



Key References and Non-GAAP Financial Measures

New product sales, **new product launches** or **new product revenues:** Refers to revenue from new products launched in 2026 and the carryover impact of new products, including business development, launched within the last 12 months.

Operational change: Refers to constant currency percentage changes and is derived by translating amounts for the current period at prior year comparative period exchange rates and in doing so shows the percentage change from 2026 constant currency net sales, total revenues, adjusted EBITDA, and adjusted EPS to the corresponding amount in the prior year.

Transaction costs or **transaction-related costs:** Refers to the impact of any acquisition and divestiture-related transaction costs, including taxes.

Restructuring costs or **restructuring-related costs:** Refers to the impact of any cash costs associated with the restructuring activities of the enterprise-wide strategic review, which are expected to be primarily related to severance and employee benefits expense, as well as other costs, including those related to contract terminations, vendor consolidations, product transfer costs and network related simplification and modernization costs.

Revenue and Earnings: Refers to Total Revenues, Adjusted EBITDA and Adjusted EPS.

Viatris Non-GAAP Financial Measures
This presentation includes the presentation and discussion of certain financial information that differs from what is reported under accounting principles generally accepted in the United States ("U.S. GAAP"). These non-GAAP financial measures, including, but not limited to, adjusted EBITDA, free cash flow, free cash flow excluding transaction-related and restructuring-related costs, adjusted EPS, adjusted gross margin, adjusted gross profit, adjusted SG&A and as a percentage of total revenues, adjusted R&D and as a percentage of total revenues, adjusted net earnings, adjusted effective tax rate, adjusted earnings from operations, adjusted interest expense, adjusted other income, net, constant currency total revenues, constant currency net sales, notional debt, gross leverage ratio and long-term gross leverage ratio target, are presented in order to supplement investors' and other readers' understanding and assessment of the financial performance of Viatris. Free cash flow refers to U.S. GAAP net cash provided by operating activities less capital expenditures. Free cash flow excluding transaction-related costs or restructuring-related costs refers to free cash flow, further adjusted to exclude transaction-related or restructuring-related costs, as applicable. Adjusted EBITDA refers to as U.S. GAAP net earnings (loss) adjusted for income tax provision (benefit), interest expense and depreciation and amortization (to calculate EBITDA) and further adjusted for share-based compensation expense, litigation settlements and other contingencies, net, loss on divestitures of businesses, impairment of goodwill and restructuring, acquisition and divestiture related and other special items. Adjusted EBITDA margins refers to adjusted EBITDA divided by total revenues. Adjusted EPS refers to adjusted net earnings divided by the weighted average number of diluted shares of common stock outstanding. Notional gross debt is the sum of the Company's long-term debt, including current portion, and short-term borrowings and other current obligations, adjusted for net premiums or discounts on various debt issuances and deferred financing fees. Viatris has provided reconciliations of such non-GAAP financial measures to the most directly comparable U.S. GAAP financial measures. Investors and other readers are encouraged to review the related U.S. GAAP financial measures and the reconciliations of the non-GAAP measures to their most directly comparable U.S. GAAP measures set forth in this presentation or on our website at https://investor.viatris.com/financial-information/non-gaap-reconciliations, and investors and other readers should consider non-GAAP measures only as supplements to, not as substitutes for or as superior measures to, the measures of financial performance prepared in accordance with U.S. GAAP.

Pacira BioSciences Non-GAAP Financial Measures
See slide 22 for information.

2026 Guidance
The Company is not providing forward-looking guidance for U.S. GAAP net earnings (loss) or U.S. GAAP diluted earnings (loss) per share ("EPS") or a quantitative reconciliation of its 2026 adjusted EBITDA or adjusted EPS guidance to the most directly comparable U.S. GAAP measures, U.S. GAAP net earnings (loss) or U.S. GAAP diluted EPS, respectively, because it is unable to predict with reasonable certainty the ultimate outcome of certain significant items, including integration, acquisition and divestiture-related expenses, restructuring expenses, asset impairments, litigation settlements, future share repurchases, and other contingencies, such as changes to contingent consideration, acquired IPR&D and certain other gains or losses, as well as related income tax accounting, because certain of these items have not occurred, are out of the Company's control and/or cannot be reasonably predicted without unreasonable effort. These items are uncertain, depend on various factors, and could have a material impact on U.S. GAAP reported results for the guidance period. 2026 financial guidance as provided on November 5, 2026 excludes the impact any acquired IPR&D for unsigned deals to be incurred in any future period as it cannot be reasonably forecasted. Also excludes any contribution from the proposed acquisition of Pacira Biosciences.

Key Exchange Rates
Our 2026 financial guidance is based on the following budgeted exchange rates: Euro ($/EUR) 0.87, China Renminbi ($/CNY) 7.19, Japanese Yen ($/JPY) 144.35, and Indian Rupee ($/INR) 85.80.

Note: Certain amounts in this presentation may not add up due to rounding. All percentages have been calculated using unrounded amounts.

VIATRIS™

© 2026 Viatris Inc. All Rights Reserved.

Full Year 2026 Financial Guidance Items as of November 5, 2026

	GAAP	Non-GAAP (1)
Total Revenues	$14,700 - $14,900	N/A
Adjusted EBITDA	N/A	$4,450 - $4,550
Net Cash Provided by Operating Activities	$2,025 - $2,100	N/A
Free Cash Flow Ex Transaction and Restructuring Costs	N/A	$2,225 - $2,375
Adjusted EPS	N/A	$2.56 - $2.63

© 2026 Viatris Inc. All Rights Reserved.

For key references and non-GAAP financial measures, see slide 2

(1) 2026 financial guidance as provided on November 5, 2026 excludes the estimated impact of transaction-related and restructuring-related costs of ~$600M. Also excludes any acquired IPR&D for unsigned deals to be incurred in any future period as it cannot be reasonably forecasted. Also excludes any contribution from the proposed acquisition of Pacira BioSciences.

Reconciliation of Estimated 2026 U.S. GAAP Net Cash Provided by Operating Activities to Free Cash Flow as of November 5, 2026

Estimated U.S. GAAP Net Cash Provided by Operating Activities	$2,025 - $2,100
Less: Capital Expenditures	($325) - ($400)
Free Cash Flow	$1,625 - $1,775
Add: Estimated Transaction and Restructuring Costs	~$600
Free Cash Flow Excluding Transaction and Restructuring Costs	$2,225 - $2,375

For key references and non-GAAP financial measures, see slide 2

© 2026 Viatris Inc. All Rights Reserved.

Full Year 2026 Financial Guidance Items as of August 6, 2026

	GAAP	Non-GAAP (1)
Total Revenues	$14,550 - $14,950	N/A
Adjusted EBITDA	N/A	$4,300 - $4,500
Net Cash Provided by Operating Activities	$1,900 - $2,100	N/A
Free Cash Flow Ex Transaction and Restructuring Costs	N/A	$2,050 - $2,350
Adjusted EPS	N/A	$2.45 - $2.59

© 2026 Viatris Inc. All Rights Reserved.

For key references and non-GAAP financial measures, see slide 2

(1) 2026 financial guidance and key metrics as provided on August 6, 2026, excluded the estimated impact of transaction-related and restructuring-related costs of ~$600M. Also excluded any acquired IPR&D for unsigned deals to be incurred in any future period as it could not be reasonably forecasted.

Reconciliation of Estimated 2026 U.S. GAAP Net Cash Provided by Operating Activities to Free Cash Flow as of August 6, 2026

Estimated U.S. GAAP Net Cash Provided by Operating Activities	$1,900 - $2,100
Less: Capital Expenditures	($350) - ($450)
Free Cash Flow	$1,450 - $1,750
Add: Estimated Transaction and Restructuring Costs	~$600
Free Cash Flow Excluding Transaction and Restructuring Costs	$2,050 - $2,350

For key references and non-GAAP financial measures, see slide 2

© 2026 Viatris Inc. All Rights Reserved.

U.S. GAAP Net Loss to Adjusted Net Earnings and U.S. GAAP Diluted Loss Per Share to Adjusted EPS

	Three Months Ended September 30,				Nine Months Ended September 30,			
	2026		2025		2026		2025	
U.S. GAAP net loss and U.S. GAAP diluted loss per share	$ (325.3)	$ (0.28)	$ (128.2)	$ (0.11)	$ (267.7)	$ (0.23)	$ (3,174.8)	$ (2.70)
Purchase accounting amortization (primarily included in cost of sales)	613.7		605.8		1,791.6		1,787.1	
Impairment of goodwill	–		–		–		2,936.8	
Litigation settlements and other contingencies, net	(11.0)		55.7		115.7		(65.4)	
Interest expense (primarily amortization of premiums and discounts on long term debt)	(10.6)		(9.9)		(30.9)		(28.6)	
(Gain) / loss on divestitures of businesses (included in other expense, net)	–		(1.6)		13.9		79.1	
Acquisition and divestiture-related costs (primarily included in cost of sales and SG&A) (a)	44.5		40.0		158.2		134.4	
Restructuring costs (b)	66.2		17.2		206.5		136.7	
Share-based compensation expense	39.6		36.0		126.5		128.3	
Other special items included in:								
Cost of sales (c)	65.8		89.4		264.5		190.1	
Research and development expense	1.7		5.6		5.6		7.7	
Selling, general and administrative expense (d)	37.2		18.0		313.7		65.7	
Other expense, net (e)	26.8		102.4		52.3		508.4	
Tax effect of the above items and other income tax related items (f)	272.8		(46.1)		(425.9)		(594.9)	
Adjusted net earnings and adjusted EPS	$ 821.4	$ 0.71	$ 784.3	$ 0.67	$ 2,324.0	$ 1.99	$ 2,110.6	$ 1.78
Weighted average diluted shares outstanding	1,160.6		1,172.2		1,169.4		1,184.0	

(a) Acquisition and divestiture-related costs consist primarily of contractual obligations related to divestitures, transaction costs including legal and consulting fees, and integration activities.
(b) For the three and nine months ended September 30, 2026, charges include approximately $19.1 million and $95.8 million, respectively, in cost of sales, approximately $0.8 million and $3.4 million, respectively, in R&D, and approximately $46.3 million and $107.3 million, respectively, in SG&A, primarily relating to the 2026 restructuring program.
(c) For the three and nine months ended September 30, 2026, includes certain asset impairments, contractual termination costs, and incremental manufacturing variances and certain remediation costs at plants slated for sale or closure or undergoing remediation activities of approximately $52.4 million and $227.3 million, respectively, including charges of $11.8 million and $98.6 million, respectively, primarily related to the write off of inventory and fixed assets damaged in the fire at the Nashik manufacturing facility and incremental manufacturing variances.
(d) For the three and nine months ended September 30, 2026, includes a (gain)/loss of $(0.8) million and $177.0 million, respectively, related to the sale of the product rights for Tyrvaya®.
(e) For the three and nine months ended September 30, 2026, charges include a pre-tax loss of approximately $27.4 million and $36.0 million, respectively, as a result of changes in the fair value and subsequent sale of the Biocon Limited equity shares.
(f) Adjusted for changes for uncertain tax positions.

VIATRIS™

© 2026 Viatris Inc. All Rights Reserved.

U.S. GAAP Net Loss to EBITDA and Adjusted EBITDA

	Three Months Ended September 30,		Nine Months Ended September 30,	
	2026	2025	2026	2025
U.S. GAAP net loss	$ (325.3)	$ (128.2)	$ (267.7)	$ (3,174.8)
Add / (deduct) adjustments:				
Income tax provision (benefit)	453.2	120.3	84.3	(147.2)
Interest expense (a)	112.4	119.6	353.2	351.7
Depreciation and amortization (b)	697.2	688.5	2,045.6	2,031.5
EBITDA	$ 937.5	$ 800.2	$ 2,215.4	$ (938.8)
Add / (deduct) adjustments:				
Share-based compensation expense	39.6	36.0	126.5	128.3
Litigation settlements and other contingencies, net	(11.0)	55.7	115.7	(65.4)
(Gain) / loss on divestitures of businesses	–	(1.6)	13.9	79.1
Impairment of goodwill	–	–	–	2,936.8
Restructuring, acquisition and divestiture-related and other special items (c)	229.6	264.3	962.0	1,016.9
Adjusted EBITDA	$ 1,195.7	$ 1,154.6	$ 3,433.5	$ 3,156.9

(a) Includes amortization of premiums and discounts on long-term debt.
(b) Includes purchase accounting related amortization.
(c) See items detailed in the Reconciliation of U.S. GAAP Net Loss to Adjusted Net Earnings.

© 2026 Viatris Inc. All Rights Reserved.

Summary of Total Revenues by Segment – Q3 2026

	Three Months Ended September 30,					
	2026	2025	% Change	2026 Currency Impact (a)	2026 Constant Currency Revenues	Constant Currency % Change (b)
Net sales						
Developed Markets	$ 2,215.9	$ 2,255.6	(2)%	$ 16.3	$ 2,232.2	(1)%
Greater China	702.6	615.2	14 %	(26.3)	676.3	10 %
JANZ	287.1	306.3	(6)%	5.0	292.1	(5)%
Emerging Markets	529.1	570.4	(7)%	6.9	536.0	(6)%
Total net sales	$ 3,734.7	$ 3,747.5	– %	$ 1.9	$ 3,736.6	– %
Other revenues (c)	14.8	12.4	NM	0.3	15.1	NM
Consolidated total revenues (d)	$ 3,749.5	$ 3,759.9	– %	$ 2.2	$ 3,751.7	– %

(a) Currency impact is shown as unfavorable (favorable).
(b) The constant currency percentage change is derived by translating net sales or revenues for the current period at prior year comparative period exchange rates, and in doing so shows the percentage change from 2026 constant currency net sales or revenues to the corresponding amount in the prior year.
(c) For the three months ended September 30, 2026, other revenues in Developed Markets, JANZ, and Emerging Markets were approximately $8.9 million, $3.9 million, and $2.0 million, respectively.
(d) Amounts exclude intersegment revenue which eliminates on a consolidated basis.

VIATRIS™

© 2026 Viatris Inc. All Rights Reserved.

Summary of Total Revenues by Segment – Q3 2026 YTD

	Nine Months Ended September 30,					
	2026	2025	% Change	2026 Currency Impact (a)	2026 Constant Currency Revenues	Constant Currency % Change (b)
Net sales						
Developed Markets	$ 6,430.4	$ 6,266.6	3 %	$ (132.3)	$ 6,298.1	1 %
Greater China	2,096.5	1,759.6	19 %	(80.5)	2,016.0	15 %
JANZ	856.6	888.1	(4)%	9.3	865.9	(2)%
Emerging Markets	1,606.8	1,645.4	(2)%	(5.6)	1,601.2	(3)%
Total net sales	$ 10,990.3	$ 10,559.7	4 %	$ (209.1)	$ 10,781.2	2 %
Other revenues (c)	33.0	36.6	NM	0.1	33.1	NM
Consolidated total revenues (d)	$ 11,023.3	$ 10,596.3	4 %	$ (209.0)	$ 10,814.3	2 %

(a) Currency impact is shown as unfavorable (favorable).
(b) The constant currency percentage change is derived by translating net sales or revenues for the current period at prior year comparative period exchange rates, and in doing so shows the percentage change from 2026 constant currency net sales or revenues to the corresponding amount in the prior year.
(c) For the nine months ended September 30, 2026, other revenues in Developed Markets, JANZ, and Emerging Markets were approximately $23.4 million, $4.1 million, and $5.5 million, respectively.
(d) Amounts exclude intersegment revenue which eliminates on a consolidated basis.

VIATRIS™

© 2026 Viatris Inc. All Rights Reserved.

Key Product Net Sales, on a Consolidated Basis

	Three Months Ended September 30,		Nine Months Ended September 30,	
	2026	2025	2026	2025
Select Key Global Products				
Lipitor ®	$ 451.9	$ 396.1	$ 1,366.1	$ 1,172.0
Norvasc ®	190.2	179.7	600.4	534.7
EpiPen ® Auto-Injectors	155.8	157.2	386.1	390.7
Lyrica ®	114.2	126.5	355.4	367.2
Creon ®	98.1	93.1	292.9	266.9
Viagra ®	94.1	105.2	302.0	304.0
Zoloft ®	78.8	66.8	222.8	188.1
Celebrex ®	70.2	73.3	213.7	206.7
Effexor ®	63.9	67.2	192.6	189.6
Xalabrands	43.9	38.6	121.9	116.4
Select Key Segment Products				
Influvac ®	$ 90.6	$ 125.4	$ 100.5	$ 130.8
Yupelri ®	71.5	71.4	204.7	196.3
Xanax ®	36.6	34.2	109.5	100.4
Amitiza ®	36.4	40.8	109.8	115.7
Dymista ®	35.4	33.8	112.5	125.0

(a) The Company does not disclose net sales for any products considered competitively sensitive.
(b) Products disclosed may change in future periods, including as a result of seasonality, competition or new product launches.
(c) Amounts include the impact of foreign currency fluctuations compared to the prior year period.

VIATRIS™
© 2026 Viatris Inc. All Rights Reserved.

Cost of Sales

	Three Months Ended September 30,		Nine Months Ended September 30,	
	2026	**2025**	**2026**	**2025**
U.S. GAAP cost of sales	$ 2,311.5	$ 2,388.4	$ 6,971.6	$ 6,730.7
Deduct:				
Purchase accounting amortization and other related items	(613.7)	(605.8)	(1,791.6)	(1,787.1)
Acquisition and divestiture-related costs	(38.8)	(23.6)	(99.2)	(62.2)
Restructuring costs	(19.1)	(13.4)	(95.8)	(44.5)
Share-based compensation expense	(0.6)	(0.7)	(2.4)	(2.9)
Other special items, including restructuring related costs	(65.8)	(89.4)	(264.5)	(190.1)
Adjusted cost of sales	$ 1,573.5	$ 1,655.5	$ 4,718.1	$ 4,643.9
Adjusted gross profit (a)	$ 2,176.0	$ 2,104.4	$ 6,305.2	$ 5,952.4
Adjusted gross margin (a)	58%	56%	57%	56%

(a) U.S. GAAP gross profit is calculated as total revenues less U.S. GAAP cost of sales. U.S. GAAP gross margin is calculated as U.S. GAAP gross profit divided by total revenues. Adjusted gross profit is calculated as total revenues less adjusted cost of sales. Adjusted gross margin is calculated as adjusted gross profit divided by total revenues.

© 2026 Viatris Inc. All Rights Reserved.

SG&A

	Three Months Ended September 30,		Nine Months Ended September 30,	
	2026	**2025**	**2026**	**2025**
U.S. GAAP SG&A	$ 950.8	$ 886.6	$ 3,014.1	$ 2,763.4
Deduct:				
Acquisition and divestiture-related costs	(4.7)	(10.6)	(54.8)	(63.1)
Restructuring costs	(46.3)	(3.7)	(107.3)	(90.0)
Share-based compensation expense	(36.8)	(33.8)	(117.1)	(119.4)
Other special items and reclassifications	(37.2)	(18.0)	(313.7)	(65.7)
Adjusted SG&A	$ 825.8	$ 820.5	$ 2,421.2	$ 2,425.2
Adjusted SG&A as % of total revenues	22%	22%	22%	23%

© 2026 Viatris Inc. All Rights Reserved.

R&D

	Three Months Ended September 30,		Nine Months Ended September 30,	
	2026	**2025**	**2026**	**2025**
U.S. GAAP R&D	$ 231.7	$ 250.4	$ 728.6	$ 691.2
Deduct:				
Acquisition and divestiture-related costs	(1.3)	(5.7)	(4.4)	(9.0)
Restructuring costs	(0.8)	–	(3.4)	(2.2)
Share-based compensation expense	(2.2)	(1.4)	(7.0)	(5.9)
Other special items	(1.7)	(5.6)	(5.6)	(7.7)
Adjusted R&D	$ 225.7	$ 237.7	$ 708.2	$ 666.4
Adjusted R&D as % of total revenues	6%	6%	6%	6%

© 2026 Viatris Inc. All Rights Reserved.

Total Operating Expenses

	Three Months Ended September 30,		Nine Months Ended September 30,	
	2026	**2025**	**2026**	**2025**
U.S. GAAP total operating expenses	$ 1,176.5	$ 1,192.7	$ 3,863.6	$ 6,336.0
Add / (Deduct):				
Litigation settlements and other contingencies, net	11.0	(55.7)	(115.7)	65.4
R&D adjustments	(6.0)	(12.7)	(20.4)	(24.8)
SG&A adjustments	(125.0)	(66.1)	(592.9)	(338.2)
Impairment of goodwill adjustments	–	–	–	(2,936.8)
Adjusted total operating expenses	$ 1,056.5	$ 1,058.2	$ 3,134.6	$ 3,101.6
Adjusted earnings from operations (a)	$ 1,119.5	$ 1,046.2	$ 3,170.6	$ 2,850.8

(a) U.S. GAAP earnings from operations is calculated as U.S. GAAP gross profit less U.S. GAAP total operating expenses. Adjusted earnings from operations is calculated as adjusted gross profit less adjusted total operating expenses.

© 2026 Viatris Inc. All Rights Reserved.

Interest Expense

	Three Months Ended September 30,		Nine Months Ended September 30,	
	2026	**2025**	**2026**	**2025**
U.S. GAAP interest expense	$ 112.4	$ 119.6	$ 353.2	$ 351.7
Add / (Deduct):				
Accretion of contingent consideration liability	(0.8)	(1.1)	(2.6)	(3.5)
Amortization of premiums and discounts on long-term debt	11.7	11.7	35.2	34.1
Other special items	(0.2)	(0.7)	(1.6)	(2.0)
Adjusted interest expense	$ 123.1	$ 129.5	$ 384.2	$ 380.3

© 2026 Viatris Inc. All Rights Reserved.

Other Expense, Net

	Three Months Ended September 30,		Nine Months Ended September 30,	
	2026	**2025**	**2026**	**2025**
U.S. GAAP other expense, net	$ 21.2	$ 67.1	$ 18.3	$ 499.9
Add / (Deduct):				
Fair value adjustments on non-marketable equity investments	–	(100.0)	–	(499.8)
Fair value adjustments on marketable equity investments	(27.4)	–	(36.0)	–
Gain (loss) on divestitures of businesses	–	1.6	(13.9)	(79.1)
Other items	0.9	(2.6)	(16.1)	(8.7)
Adjusted other income, net	$ (5.3)	$ (33.9)	$ (47.7)	$ (87.7)

© 2026 Viatris Inc. All Rights Reserved.

Earnings (Loss) Before Income Taxes and Income Tax Provision (Benefit)

	Three Months Ended September 30,		Nine Months Ended September 30,	
	2026	**2025**	**2026**	**2025**
U.S. GAAP earnings (loss) before income taxes	$ 127.9	$ (7.9)	$ (183.4)	$ (3,322.0)
Total pre-tax non-GAAP adjustments	873.8	958.5	3,017.5	5,880.3
Adjusted earnings before income taxes	$ 1,001.7	$ 950.6	$ 2,834.1	$ 2,558.3
U.S. GAAP income tax provision (benefit)	$ 453.2	$ 120.3	$ 84.3	$ (147.2)
Adjusted tax (benefit) expense	(272.9)	46.1	425.8	594.9
Adjusted income tax provision	$ 180.3	$ 166.4	$ 510.1	$ 447.7
Adjusted effective tax rate	18.0%	17.5%	18.0%	17.5%

© 2026 Viatris Inc. All Rights Reserved.

Free Cash Flow and Free Cash Flow Excluding Transaction-related and Restructuring-related Costs

	Three Months Ended September 30,		Nine Months Ended September 30,	
	2026	2025	2026	2025
U.S. GAAP net cash provided by operating activities	$ 899.4	$ 744.9	$ 1,669.5	$ 1,500.1
Capital expenditures	(85.7)	(86.8)	(178.4)	(182.3)
Free cash flow	$ 813.7	$ 658.1	$ 1,491.1	$ 1,317.8
Transaction-related and restructuring-related costs	81.1	69.6	311.9	185.9
Free cash flow excluding transaction-related and restructuring-related costs	$ 894.8	$ 727.7	$ 1,803.0	$ 1,503.7

VIATRIS™
© 2026 Viatris Inc. All Rights Reserved.

Gross Leverage – Debt to Adjusted EBITDA – Q3 2026

Gross Leverage Ratio is the ratio of Viatris' total debt at notional amounts at September 30, 2026 to the sum of Viatris' adjusted EBITDA for the quarters ended December 31, 2025, March 31, 2026, June 30, 2026, and September 30, 2026.

	Three Months Ended				Twelve Months Ended
	December 31, 2025	March 31, 2026	June 30, 2026	September 30, 2026	September 30, 2026
Adjusted EBITDA	$ 1,003.1	$ 1,049.5	$ 1,188.3	$ 1,195.7	$ 4,436.6
Reported debt balances:					
Long-term debt, including current portion					13,312.3
Short-term borrowings and other current obligations					–
Total					$ 13,312.3
Add / (deduct):					
Net premiums on various debt issuances					(411.9)
Deferred financing fees					23.6
Total debt at notional amounts					$ 12,924.0
Gross debt to adjusted EBITDA					2.9 x

Long-term Gross Leverage Target

The stated forward-looking non-GAAP financial measure of long-term gross leverage target range of 2.8x-3.2x is based on the ratio of (i) targeted notional gross debt and (ii) targeted adjusted EBITDA. However, the Company has not quantified future amounts to develop this target but has stated its goal to manage notional gross debt and adjusted EBITDA over time in order to generally maintain or reach the target. This target does not reflect Company guidance.

VIATRIS™

© 2026 Viatris Inc. All Rights Reserved.

Viatris Inc. and Subsidiaries | Reconciliation of Non-GAAP Financial Measures (Unaudited; in millions)

Net (Loss) Earnings to EBITDA and Adjusted EBITDA – Last Twelve Months

	Three Months Ended			
	December 31, 2025	March 31, 2026	June 30, 2026	September 30, 2026
U.S. GAAP net (loss) earnings	$ (340.1)	$ 176.4	$ (118.8)	$ (325.3)
Add / (deduct) adjustments:				
Income tax (benefit) provision	(2.9)	(423.7)	54.8	453.2
Interest expense (a)	119.6	120.1	120.7	112.4
Depreciation and amortization (b)	766.8	676.1	672.3	697.2
EBITDA	$ 543.4	$ 548.9	$ 729.0	$ 937.5
Add / (deduct) adjustments:				
Share-based compensation expense	49.4	48.2	38.7	39.6
Litigation settlements and other contingencies, net	(3.1)	53.5	73.2	(11.0)
Loss on divestitures of businesses	21.9	13.9	–	–
Restructuring, acquisition and divestiture-related and other special items	391.5	385.0	347.4	229.6
Adjusted EBITDA	$ 1,003.1	$ 1,049.5	$ 1,188.3	$ 1,195.7

(a) Includes amortization of premiums and discounts on long-term debt.
(b) Includes purchase accounting related amortization.

© 2026 Viatris Inc. All Rights Reserved.

Pacira BioSciences, Inc. | Reconciliation of Non-GAAP Financial Measures (Unaudited; in millions)

Net Income to Adjusted EBITDA – Twelve Months Ended June 30, 2026

Pacira BioSciences Non-GAAP Financial Measures
This presentation contains a Pacira financial measure that does not comply with U.S. GAAP, adjusted EBITDA (earnings before interest, taxes, depreciation and amortization), because this non-GAAP financial measure excludes the impact of items that Pacira's management believes affect comparability or underlying business trends.

This measure supplements Pacira's financial results prepared in accordance with U.S. GAAP. Pacira management uses this measure to better analyze its financial results and to help make managerial decisions. In Pacira's management's opinion, this non-GAAP measure is useful to investors and other users of Pacira's financial statements by providing greater transparency into the ongoing operating performance of Pacira and its future outlook. Such a measure should not be deemed to be an alternative to U.S. GAAP requirements or a measure of liquidity for Pacira. The non-GAAP measure presented here is also unlikely to be comparable with non-GAAP disclosures released by other companies.

The Pacira financial measures included herein are consistent with such measures as reported in Pacira's earnings releases as furnished to the SEC. A reconciliation of Pacira's adjusted EBITDA, a non-GAAP financial measure, to the most directly comparable U.S. GAAP financial measure, U.S. GAAP net income (loss), is set forth below.

	Three Months Ended				Twelve Months Ended
	September 30, 2025	December 31, 2025	March 31, 2026	June 30, 2026	June 30, 2026
U.S. GAAP Net Income	$ 5.4	$ 1.6	$ 2.9	$ 4.7	$ 14.6
Interest Income	(8.5)	(2.3)	(1.9)	(1.9)	(14.7)
Interest Expense	4.3	3.9	3.7	3.6	15.5
Income Tax Expense	4.1	(1.1)	2.1	(2.1)	3.0
Depreciation Expense	6.9	7.0	7.0	7.0	27.9
Amortization of Acquired Intangible Assets	14.3	14.3	14.3	14.3	57.3
EBITDA	$ 26.5	$ 23.5	$ 28.1	$ 25.5	$ 103.6
Other Adjustments:					
Divestiture and Acquisition-Related Expenses, and Other	7.3	1.4	0.9	6.5	16.1
Changes in the Fair Value of Contingent Consideration	0.6	0.2	(2.3)	1.7	0.2
Stock-Based Compensation	14.0	13.5	13.5	15.0	56.0
Loss on Early Extinguishment of Debt	1.0	-	-	-	1.0
Adjusted EBITDA	$ 49.4	$ 38.7	$ 40.2	$ 48.7	$ 177.0

VIATRIS™

© 2026 Viatris Inc. All Rights Reserved.